Home About us Contact
|
Home About us Contact | ||
|
|
||
Oral Bioavailability (oral + bioavailability)
Kinds of Oral Bioavailability Selected AbstractsOral bioavailability and toxicokinetics of 3,3,,4,4,,5-pentachlorobiphenyl in northern leopard frogs, Rana pipiensENVIRONMENTAL TOXICOLOGY & CHEMISTRY, Issue 7 2000Yue-wern Huang Abstract This study is the first report on oral bioavailability, whole-body elimination, and distribution of a specific polychlorinated biphenyl (PCB) congener on an amphibian species, northern leopard frogs. Each frog was orally dosed once with either 0.35 or 5.0 mg/kg PCB 126 (based on frog wet wt), including tracer 14C-PCB 126 (3,,4,,5,-phenyl-ring- 14C) by force feeding it a cricket injected with the PCB. We found no statistical difference (t = 0.917, df = 5, p = 0.401) in the average 48-h oral bioavailabilities of 0.35- and 5.0-mg/kg dosage groups, which were 84.6 ± 5.8% (mean ± SE, n = 4) and 90.9 ± 1.5% (n = 3), respectively. Statistical analysis indicated that time was the only independent variable affecting the retention of whole-body 14C content. Kinetics were apparently first order because elimination rate was independent of dose. Assuming a single pool and one elimination rate, the t1/2 value for whole-body elimination of PCB-derived 14C was 763 d. Liver, fat bodies (corpora adiposa), carcass (head, bone, cartilage materials, and residues of other tissues), skin, and muscle were the major organs for PCB 126 retention in both dosage groups. The concentrations of 14C residue in fat bodies were relatively constant throughout the experiment. However, total residues in fat bodies declined throughout the experiment in both dosage groups in correlation with declining masses of fat bodies. Gonad, kidney, stomach, intestine, and a tissue pool including esophagus, lung, spleen, heart, and cloacal materials each accumulated <1% of the initial total 14C residue. The egg follicles in 19 females contained 1 to 23% of the initial total 14C residue, with an average of 10.0 ± 9.2% (mean ± SE, n = 19). [source] Clinical Pharmacokinetics of FrovatriptanHEADACHE, Issue 2002P. Buchan PhD Objective.,To review available data on the clinical pharmacokinetics of frovatriptan. Background.,Preclinical data suggest that the pharmacokinetic profile of frovatriptan may differ from that of the currently available triptans. Methods.,Studies of healthy volunteers, subjects with renal or hepatic impairment, elderly subjects, and patients with migraine during and between attacks were reviewed. Results.,Oral bioavailability of frovatriptan is 22% to 30%, and although the time to maximum concentration is typically 2 to 3 hours, approximately 60% to 70% of plasma maximum concentration is achieved within 1 hour of dosing. Frovatriptan distributes into erythrocytes, with binding reversible and time dependent. The relatively long terminal elimination half-life (about 26 hours) confers good systemic exposure and may produce a long duration of therapeutic action, thus reducing migraine recurrence and the need for redosing. Systemic exposure to frovatriptan generally correlates with dose between 1 and 100 mg. Blood and plasma frovatriptan concentrations are consistently higher in females, but there is no need to adjust dose according to gender. Pharmacokinetics are essentially unaffected by food and were predictable after repeat dosing; steady state is approached in about 4 to 5 days. Pharmacokinetics were changed only slightly in subjects with renal impairment or mild-to-moderate hepatic impairment, elderly individuals, and during migraine attacks. Frovatriptan is principally metabolized by the CYP1A2 isoenzyme of cytochrome P-450 and is cleared by the kidney and liver, each having sufficient capacity to compensate for impairment of the other. Conclusions.,Frovatriptan can be taken without regard for food intake, and because of the large therapeutic margin and shallow dose-response curve, there is no need for dosage adjustment in the elderly, in women taking a combined oral contraceptive, in patients with mild-to-severe renal impairment, mild-to-moderate hepatic impairment, or according to gender. The long duration of exposure may reduce the likelihood of early migraine recurrence. [source] Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulationsJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 10 2007Héctor R. Guzmán Abstract Biopharmaceutical evaluation of crystalline celecoxib salts in novel solid formulations, which were designed to simultaneously facilitate dissolution and inhibit precipitation in vitro, showed fast and complete absorption in beagle dogs at doses up to 7.5 mg/kg orally. In contrast, 5 mg/kg celecoxib in the form of Celebrex® showed approximately 40% absolute bioavailability in a cross-over experiment. An in vitro,in vivo correlation was observed in dog, and a threshold level of in vitro dissolution needed to maximize in vivo performance was highlighted. Oral bioavailability was limited in the absence of excipient combinations that delayed precipitation of celecoxib free acid as the salt neutralized in the GI fluid. Formulations of crystal forms having high energy (a ,spring'), thus transiently increasing solubility in aqueous solution relative to the free acid, combined with excipients functioning as precipitation inhibitors (,parachutes') were shown to provide both enhanced dissolution and high oral bioavailability. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96: 2686,2702, 2007 [source] Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogsJOURNAL OF VETERINARY PHARMACOLOGY & THERAPEUTICS, Issue 5 2004B. KuKanich Dextromethorphan is an N -methyl- d -aspartate (NMDA) noncompetitive antagonist which has been used as an antitussive, analgesic adjunct, probe drug, experimentally to attenuate acute opiate and ethanol withdrawal, and as an anticonvulsant. A metabolite of dextromethorphan, dextrorphan, has been shown to behave pharmacodynamically in a similar manner to dextromethorphan. The pharmacokinetics of dextromethorphan were examined in six healthy dogs following intravenous (2.2 mg/kg) and oral (5 mg/kg) administration in a randomized crossover design. Dextromethorphan behaved in a similar manner to other NMDA antagonists upon injection causing muscle rigidity, ataxia to recumbency, sedation, urination, and ptyalism which resolved within 90 min. One dog repeatedly vomited upon oral administration and was excluded from oral analysis. Mean ± SD values for half-life, apparent volume of distribution, and clearance after i.v. administration were 2.0 ±0.6 h, 5.1 ± 2.6 L/kg, and 33.8 ± 16.5 mL/min/kg. Oral bioavailability was 11% as calculated from naïve pooled data. Free dextrorphan was not detected in any plasma sample, however enzymatic treatment of plasma with glucuronidase released both dextromethorphan and dextrorphan indicating that conjugation is a metabolic route. The short half-life, rapid clearance, and poor bioavailability of dextromethorphan limit its potential use as a chronic orally administered therapeutic. [source] Isoxsuprine hydrochloride in the horse: a reviewJOURNAL OF VETERINARY PHARMACOLOGY & THERAPEUTICS, Issue 2 2002R. S. ERKERT Isoxsuprine hydrochloride has been suggested for use in horses for treatment of navicular syndrome and laminitis. The drug has been shown to be a , -adrenoreceptor antagonist with , -adrenoreceptor agonistic properties, with both characteristics contributing to vasodilation and uterine relaxation. In addition, the drug is capable of decreasing blood viscosity and platelet aggregation. Studies have shown i.v. isoxsuprine to have a plasma half-life of <3 h with a large apparent volume of distribution. Cardiovascular effects resolve rapidly following i.v. administration, but are absent with oral dosing. Oral bioavailability is 2.2% with a high first pass effect. Isoxsuprine has an apparent affinity for melanin that may contribute to extended renal excretion. Clinical trials appear to support the use of isoxsuprine for treatment of navicular disease. However, poor bioavailability, lack of cardiovascular effects following oral administration, superficial support in clinical trials, and new evidence regarding the pathogenesis of navicular syndrome indicate that the use of isoxsuprine for treatment of navicular syndrome or laminitis is questionable at best. [source] Oral administration of a centrally acting ghrelin receptor agonist to conscious rats triggers defecationNEUROGASTROENTEROLOGY & MOTILITY, Issue 1 2009A. D. Shafton Abstract, Agonists of ghrelin receptors that cross the blood,brain barrier, but not ghrelin itself, administered peripherally (intravenous or subcutaneous), cause defecation by acting on centres in the lumbo-sacral spinal cord. It is not established whether orally administered ghrelin receptor agonists can have this action. We tested GSK894281 for its effectiveness at the ghrelin receptor and its ability to cross the blood,brain barrier. GSK894281 was effective at the human and rat ghrelin receptors at 1,10 nmol L,1, but was >1000-fold less potent at the motilin receptor. It achieved a similar blood concentration by oral or intravenous administration. Oral bioavailability was 74% and brain : blood ratio at steady state was 0.7 : 1. GSK894281 administered orally (1,100 mg kg,1) caused a prompt, dose-related production of faecal pellets; at 10 mg kg,1 faecal output was four times greater than after carrier. The output was the greatest in the first half hour and subsided over the next 90 min. At an oral dose of 10 mg kg,1, the compound was effective on eight successive days. Faecal output was, on average, increased threefold over control in the 2 h after administration on each of the 8 days. This dose also significantly increased food consumption. Rats showed no adverse behavioural effects to the drug on a single application, but at the end of a week of administration they avoided the gavaging pipette. Oral administration of ghrelin receptor agonists that enter the central nervous system could possibly be used to relieve acute cases of constipation or to clear the bowel for colonoscopy. [source] The absorption, distribution, metabolism and elimination of bevirimat in ratsBIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 7 2008Peter Bullock Abstract Bevirimat is the first drug in the class of maturation inhibitors, which treat HIV infection by disrupting the activity of HIV protease enzyme with a mechanism of action distinct from that of conventional protease inhibitors. The absorption, distribution, metabolism and elimination characteristics of single intravenous (25,mg/kg) and oral (25,mg/kg and 600,mg/kg) doses of 14C-bevirimat were studied in male Sprague Dawley and Long Evans rats. Pharmacokinetic and mass-balance studies revealed that bevirimat was cleared rapidly (within 12,24,h) after dosing, although plasma radioactivity was quantifiable up to 168,h. Radioactive metabolites of bevirimat were responsible for approximately 60,80% of plasma radioactivity. Systemically available bevirimat was predominantly (97%) excreted via bile in the faeces, with ,1% of the dose excreted renally. Less than 0.1% of the dose was excreted in expired air. Quantitative whole-body autoradiography detected high quantities of radioactivity in the bile and liver soon after intravenous dose administration, and evidence of biliary excretion present during the 8,h following oral dosing. Oral bioavailability for the 25,mg/kg dose of bevirimat was estimated at 22,24% by pharmacokinetic and mass-balance methods, with bioavailability decreasing disproportionately with increasing dose for the 600,mg/kg group. Copyright © 2008 John Wiley & Sons, Ltd. [source] Pharmacokinetics of SB-247083, a potent and selective endothelinA receptor antagonist, in the rat, dog, and monkeyBIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 8 2002Keith W. Ward Abstract The endothelins (ET) are among the most potent vasoconstrictors identified to date, and have been implicated in such diseases as renal failure, pulmonary hypertension, atherosclerosis, and congestive heart failure. There is currently interest in developing selective antagonists of the ET-A subtype receptor, and one such antagonist is SB-247083 ((E)-[1-butyl-5-[2-(2-carboxyphenyl) methoxy-4-chlorophenyl]-1H-pyrazole-4-yl]-2-[5-methoxydihydrobenzofuran-6-yl]methyl]-2-propionic acid). This investigation was conducted to evaluate the preclinical pharmacokinetics of SB-247083. Clearance of SB-247083 was low to moderate in the rat and monkey, and high in the dog. Oral bioavailability of SB-247083 administered as a solid formulation of the free acid was 24% in the rat, but low in the dog (4%) and the monkey (2%). An extensive in vitro salt form and formulation screen resulted in the identification of a formulation containing the monoarginyl salt with improved dissolution properties. This formulation provided a 2- to 4-fold increase in oral bioavailability in each of the preclinical species. In the dog, this improvement was reversed by the pre-administration of 0.1 N HCl to normalize the achlorhydric fasting dog stomach. These data show that SB-247083 may have suitable drug properties for progression in development. Copyright © 2002 John Wiley & Sons, Ltd. [source] Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogsBIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 6 2001Raquel F. Reinoso Abstract The pharmacokinetics of E-6087, a newly developed cyclooxygenase-2 inhibitor, was studied in rats and dogs after single oral and intravenous doses. In both animal species, E-6087 was characterized by a long elimination half-life (20,35 h), a low plasma clearance (0.10,0.22 l h,1 kg,1) and a relatively large volume of distribution (2,6 l kg,1). Oral bioavailability was lower in dogs than in rats whereas a faster elimination was found in rats. Multiple peaks were present regardless of administration route and animal species, suggesting the existence of enterohepatic circulation. Gender effect on the pharmacokinetics of E-6087 was only found in rats, with greater exposure and longer elimination in females than in males. Food intake reduced the bioavailability (,22%) with no apparent changes in the absorption rate. After oral dosing of 1, 5 and 25 mg kg,1 to rats, linearity was lost at the highest dose due to the low aqueous solubility of E-6087. Drug absorption was improved by micronization. E-6087 and E-6132, (a pharmacologically active metabolite), showed different pharmacokinetics. The higher percentage of E-6087 at early times suggests that E-6087 is the main compound responsible for in vivo activity, although E-6132 would contribute to the activity at later times. Copyright © 2001 John Wiley & Sons, Ltd. [source] Oral bioavailability and toxicokinetics of 3,3,,4,4,,5-pentachlorobiphenyl in northern leopard frogs, Rana pipiensENVIRONMENTAL TOXICOLOGY & CHEMISTRY, Issue 7 2000Yue-wern Huang Abstract This study is the first report on oral bioavailability, whole-body elimination, and distribution of a specific polychlorinated biphenyl (PCB) congener on an amphibian species, northern leopard frogs. Each frog was orally dosed once with either 0.35 or 5.0 mg/kg PCB 126 (based on frog wet wt), including tracer 14C-PCB 126 (3,,4,,5,-phenyl-ring- 14C) by force feeding it a cricket injected with the PCB. We found no statistical difference (t = 0.917, df = 5, p = 0.401) in the average 48-h oral bioavailabilities of 0.35- and 5.0-mg/kg dosage groups, which were 84.6 ± 5.8% (mean ± SE, n = 4) and 90.9 ± 1.5% (n = 3), respectively. Statistical analysis indicated that time was the only independent variable affecting the retention of whole-body 14C content. Kinetics were apparently first order because elimination rate was independent of dose. Assuming a single pool and one elimination rate, the t1/2 value for whole-body elimination of PCB-derived 14C was 763 d. Liver, fat bodies (corpora adiposa), carcass (head, bone, cartilage materials, and residues of other tissues), skin, and muscle were the major organs for PCB 126 retention in both dosage groups. The concentrations of 14C residue in fat bodies were relatively constant throughout the experiment. However, total residues in fat bodies declined throughout the experiment in both dosage groups in correlation with declining masses of fat bodies. Gonad, kidney, stomach, intestine, and a tissue pool including esophagus, lung, spleen, heart, and cloacal materials each accumulated <1% of the initial total 14C residue. The egg follicles in 19 females contained 1 to 23% of the initial total 14C residue, with an average of 10.0 ± 9.2% (mean ± SE, n = 19). [source] Formulation and food effects on the oral absorption of a poorly water soluble, highly permeable antiretroviral agentJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 6 2002Bruce J. Aungst Abstract DPC 961 is a low-solubility, high-permeability, second-generation non-nucleoside reverse transcriptase inhibitor. The purpose of these studies was to evaluate the effects of drug substance and formulation variables on DPC 961 oral absorption, and to compare fed and fasted state oral absorption. To accomplish this, groups of four to six dogs were dosed with various formulations of DPC 961 under fasted or fed conditions, and DPC 961 pharmacokinetics were examined. Absolute oral bioavailability, based on i.v. AUC in the same dogs, was 24% after a suspension dose in fasted dogs and was 51% in fed dogs. Bioavailability with an unoptimized tablet formulation was 30% in fasted dogs and 86% in fed dogs. DPC 961 oral absorption was shown to be dependent on drug substance particle size in fasted dogs, after dosing with a tablet formulation where only the drug substance particle size was varied, but there was no difference in fed dogs. AUC and Cmax increased in proportion with increases in tablet strength from 100 to 400 mg, using tablets manufactured from a common granulation. Tablets made with 50 and 66% drug loadings showed similar relative oral bioavailabilities. Tablets prepared with two different polymorphic forms of DPC 961 were also compared, and these were found to be equivalent. These studies provided a useful component of the formulation development process, to help identify and control the variables affecting oral absorption of this potential new therapeutic agent. © 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:1390,1395, 2002 [source] Pharmacokinetics of anthraquinones in Xiexin decoction and in different combinations of its constituent herbsPHYTOTHERAPY RESEARCH, Issue 3 2009Dongming Yan Abstract Xiexin decoction (XXD), a classic pyretolysis formula, is composed of Rhei Rhizoma (DH), Radix Scutellaria (HQ) and Coptis Chinensis (HL) and is commonly used in the clinical setting. The aim of this study was to investigate the pharmacokinetic differences of the five anthraquinones in rats after oral administration of XXD and different combinations of its constituent herbs. Twenty rats were randomly divided into four groups and were administered one of the four extracts: DH, DH-HQ, DH-HL and XXD (DH-HQ-HL) via intragastric gavage. Anthraquinone concentrations in plasma were determined by an HPLC technique. Pharmacokinetic parameters were calculated from the plasma concentration,time data. Compared with DH alone, the DH-HL combination decreased Cmax of all five anthraquinones and AUC of four anthraquinones (except physcion), and the DH-HQ combination decreased AUC of aloe-emodin and Cmax of rhein. Finally, XXD increased AUC of all five anthraquinones compared with DH-HL combination. These results showed that the oral bioavailabilities of five anthraquinones were decreased significantly by combining DH with HL, whereas HQ weakened the effect of HL that inhibited the absorption of anthraquinones. Copyright © 2008 John Wiley & Sons, Ltd. [source] Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in ratsBIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 6 2002Andries Pelser Abstract The intranasal route of administration provides a potential useful way of administering a range of systemic drugs. In order to assess the feasibility of this approach for the treatment of nausea and vomiting, doxylamine succinate was studied in rats for the pharmacokinetics (AUC, Cmax, tmax) following intranasal, oral and intravenous administrations. Subjects (six male Sprague,Dawley rats per time interval for each route of administration) received 2-mg doses of doxylamine succinate orally and I-mg doses intranasally and intravenously, respectively. The various formulations were formulated in isotonic saline (0.9% w/v) at 25±1°C. Doxylamine succinate concentrations in plasma were determined with a high-performance liquid chromatographic assay and a liquid,liquid extraction procedure. Intranasal and oral bioavailabilities were determined from AUC values relative to those after intravenous dosing. Intranasal bioavailability was greater than that of oral doxylamine succinate (70.8 vs 24.7%). The intranasal and oral routes of administration differed significantly from the intravenous route of administration. Peak plasma concentration (Cmax) was 887.6 ng/ml (S.D. 74.4), 281.4 ng/ml (S.D. 24.6) and 1296.4 ng/ml (S.D. 388.9) for the intranasal, oral and intravenous routes, respectively. The time to achieve Cmax for the intranasal route (tmax=0.5 h) was faster than for the oral route (tmax=1.5 h), but no statistically significant differences between the Cmax values were found using 95% confidence intervals. The results of this study show that doxylamine succinate is rapidly and effectively absorbed from the nasal mucosa. Copyright © 2002 John Wiley & Sons, Ltd. [source] Pharmacokinetics of dipeptidylpeptidase-4 inhibitorsDIABETES OBESITY & METABOLISM, Issue 8 2010A. J. Scheen Type 2 diabetes (T2DM) is a complex disease combining defects in insulin secretion and insulin action. New compounds have been developed for improving glucose-induced insulin secretion and glucose control, without inducing hypoglycaemia or weight gain. Dipeptidylpeptidase-4 (DPP-4) inhibitors are new oral glucose-lowering agents, so-called incretin enhancers, which may be used as monotherapy or in combination with other antidiabetic compounds. Sitagliptin, vildaglipin and saxagliptin are already on the market in many countries, either as single agents or in fixed-dose combined formulations with metformin. Other DPP-4 inhibitors, such as alogliptin and linagliptin, are currently in late phase of development. The present paper summarizes and compares the main pharmacokinetics (PK) properties, that is, absorption, distribution, metabolism and elimination, of these five DPP-4 inhibitors. Available data were obtained in clinical trials performed in healthy young male subjects, patients with T2DM, and patients with either renal insufficiency or hepatic impairment. PK characteristics were generally similar in young healthy subjects and in middle-aged overweight patients with diabetes. All together gliptins have a good oral bioavailability which is not significantly influenced by food intake. PK/pharmacodynamics characteristics, that is, sufficiently prolonged half-life and sustained DPP-4 enzyme inactivation, generally allow one single oral administration per day for the management of T2DM; the only exception is vildagliptin for which a twice-daily administration is recommended because of a shorter half-life. DPP-4 inhibitors are in general not substrates for cytochrome P450 (except saxagliptin that is metabolized via CYP 3A4/A5) and do not act as inducers or inhibitors of this system. Several metabolites have been documented but most of them are inactive; however, the main metabolite of saxagliptin also exerts a significant DPP-4 inhibition and is half as potent as the parent compound. Renal excretion is the most important elimination pathway, except for linagliptin whose metabolism in the liver appears to be predominant. PK properties of gliptins, combined with their good safety profile, explain why no dose adjustment is necessary in elderly patients or in patients with mild to moderate hepatic impairment. As far as patients with renal impairment are concerned, significant increases in drug exposure for sitagliptin and saxagliptin have been reported so that appropriate reductions in daily dosages are recommended according to estimated glomerular filtration rate. The PK characteristics of DPP-4 inhibitors suggest that these compounds are not exposed to a high risk of drug,drug interactions. However, the daily dose of saxagliptin should be reduced when coadministered with potent CYP 3A4 inhibitors. In conclusion, besides their pharmacodynamic properties leading to effective glucose-lowering effect without inducing hypoglycaemia or weight gain, DPP-4 inhibitors show favourable PK properties, which contribute to a good efficacy/safety ratio for the management of T2DM in clinical practice. [source] Long circulating nanoparticles of etoposide using PLGA-MPEG and PLGA-pluronic block copolymers: characterization, drug-release, blood-clearance, and biodistribution studiesDRUG DEVELOPMENT RESEARCH, Issue 4 2010Khushwant S. Yadav Abstract The anti-leukemic drug, etoposide (ETO), has variable oral bioavailability ranging from 24,74% with a short terminal half-life of 1.5,h i.v. necessitating continuous infusion for 24,34,h for the treatment of leukemia. In the present study, etoposide-loaded PLGA-based surface-modified nanoparticles (NPs) with long circulation were designed as an alternative to continuous i.v. administration. PLGA-mPEG and PLGA-PLURONIC copolymers were synthesised and used to prepared ETO-loaded NPs by high-pressure homogenization. The mean particle size of ETO-loaded PLGA-MPEG nanoparticles was 94.02±3.4,nm, with an Entrapment Efficiency (EE) of 71.2% and zeta potential value of ,6.9±1.3,mV. ETO-loaded PLGA-pluronic nanoparticles had a mean particle size of 148.0±2.1,nm, an EE of 73.12±2.7%, and zeta potential value of ,21.5±1.6,mV. In vitro release of the pure drug was complete within 4,h, but was sustained up to 7 days from PLGA-mPEG nanoparticles and for 5 days from PLGA-pluronic nanoparticles. Release was first order and followed non-Fickian diffusion kinetics in both instances. ETO and ETO-loaded PLGA nanoparticles labeled with 99mTc were used in blood clearance studies in rats where the two coated NPs, 99mTc- ETO-PLGA-PLU NP and 99mTc- ETO-PLGA-mPEG NP, were found to be available in higher concentrations in the circulation as compared to the pure drug. Biodistribution studies in mice showed that ETO-loaded PLGA-MPEG NP and PLGA-PLURONIC NP had reduced uptake by the RES due to their steric barrier properties and were present in the circulation for a longer time. Moreover, the NPs had greater uptake in bone and brain where concentration of the free drug, ETO, was negligible. Drug delivered from these NPs could result in a single i.v. injection that would release the drug for a number of days, which would be potentially beneficial and in better control of leukemia therapy. Drug Dev Res 71: 228,239, 2010. © 2010 Wiley-Liss, Inc. [source] Improving the dissolution and oral bioavailability of the poorly water-soluble drug aloe-emodin by solid dispersion with polyethylene glycol 6000DRUG DEVELOPMENT RESEARCH, Issue 5 2009Hao-gang Duan Abstract Solid dispersions (SDs) of aloe-emodin (AE) and polyethylene glycol 6000 (PEG6000) with different drug loadings were prepared, characterized by scanning electron microscopy (SEM) and differential scanning calorimetry (DSC) and evaluated for solubility and in vitro release. The oral bioavailability of AE from SD in rats was compared with the crystalline drug. Plasma concentrations of AE were determined by HPLC. After administration of crystalline AE (35,mg·kg,1) in rats, the AUC0-600 and Cmax were 393.6±77.1,mg·min·l,1 and 1.87±0.30,mg·l,1, respectively. For the PEG6000 SD of AE, AUC0-600 and Cmax were boosted to 1310.5±111.9,mg·min·l,1 and 5.86±0.47,mg·l,1, respectively. The results indicated that the oral bioavailability of AE was increased significantly. Simultaneously, the Tmax value of AE for AE crystalline was decreased from 75.6±17.3,min to 44.8±14.8,min for SD. The earlier Tmax for AE from SD indicated the higher extent of absorption for SD due to their improved dissolution rate in rat intestine. This SD approach can therefore be used to enhanced dissolution and bioavailability for poorly water-soluble drugs. Drug Dev Res, 2009. © 2009 Wiley-Liss, Inc. [source] Effect of organic carbon content, clay type, and aging on the oral bioavailability of hexachlorobenzene in rats,ENVIRONMENTAL TOXICOLOGY & CHEMISTRY, Issue 11 2007Shakil A. Saghir Abstract Bioavailability of lipophilic chemicals is influenced by the physicochemical properties of soils/sediment such as particle size, pH, clay, and organic carbon content. The present study investigated the effects of sediment composition and aging on the oral bioavailability of hexachlorobenzene (HCB) in rats. Formulated sediments were prepared using various ratios of kaolinite and montmorillonite clay, sand, peat moss, and black carbon, spiked with 14C-HCB, and orally administered to rats prior to and after one year of aging in dark at 10°C. In the nonaged sediments there was a 21 to 45% reduction in the oral bioavailability of HCB when compared to the corn oil standard without any clear pattern of the impact of the sediment clay and/or organic carbon content. One year of aging resulted in statistically significant (p = 0.049) reduction in the oral bioavailability of HCB from the sediments compared to the corn oil standard and nonaged sediment indicating stronger interactions between HCB and sediment contents with aging. The mean reduction in oral bioavailability after one year of aging ranged from approximately 5 to 14% greater than that observed for nonaged sediments. The fecal elimination of the HCB-derived radioactivity from the one-year-aged sediments was much higher than the nonaged sediments, consistent with the lower absorption from the gastrointestinal tract due to lower desorption of HCB from the aged sediments. Increase in the fecal elimination and decrease in oral bioavailability of 14C-HCB was related to the increase in clay and black carbon. [source] Oral bioavailability and toxicokinetics of 3,3,,4,4,,5-pentachlorobiphenyl in northern leopard frogs, Rana pipiensENVIRONMENTAL TOXICOLOGY & CHEMISTRY, Issue 7 2000Yue-wern Huang Abstract This study is the first report on oral bioavailability, whole-body elimination, and distribution of a specific polychlorinated biphenyl (PCB) congener on an amphibian species, northern leopard frogs. Each frog was orally dosed once with either 0.35 or 5.0 mg/kg PCB 126 (based on frog wet wt), including tracer 14C-PCB 126 (3,,4,,5,-phenyl-ring- 14C) by force feeding it a cricket injected with the PCB. We found no statistical difference (t = 0.917, df = 5, p = 0.401) in the average 48-h oral bioavailabilities of 0.35- and 5.0-mg/kg dosage groups, which were 84.6 ± 5.8% (mean ± SE, n = 4) and 90.9 ± 1.5% (n = 3), respectively. Statistical analysis indicated that time was the only independent variable affecting the retention of whole-body 14C content. Kinetics were apparently first order because elimination rate was independent of dose. Assuming a single pool and one elimination rate, the t1/2 value for whole-body elimination of PCB-derived 14C was 763 d. Liver, fat bodies (corpora adiposa), carcass (head, bone, cartilage materials, and residues of other tissues), skin, and muscle were the major organs for PCB 126 retention in both dosage groups. The concentrations of 14C residue in fat bodies were relatively constant throughout the experiment. However, total residues in fat bodies declined throughout the experiment in both dosage groups in correlation with declining masses of fat bodies. Gonad, kidney, stomach, intestine, and a tissue pool including esophagus, lung, spleen, heart, and cloacal materials each accumulated <1% of the initial total 14C residue. The egg follicles in 19 females contained 1 to 23% of the initial total 14C residue, with an average of 10.0 ± 9.2% (mean ± SE, n = 19). [source] Rufinamide: Clinical pharmacokinetics and concentration,response relationships in patients with epilepsyEPILEPSIA, Issue 7 2008Emilio Perucca Summary Rufinamide is a new, orally active antiepileptic drug (AED), which has been found to be effective in the treatment of partial seizures and drop attacks associated with the Lennox-Gastaut syndrome. When taken with food, rufinamide is relatively well absorbed in the lower dose range, with approximately dose-proportional plasma concentrations up to 1,600 mg/day, but less than dose-proportional plasma concentrations at higher doses due to reduced oral bioavailability. Rufinamide is not extensively bound to plasma proteins. During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6,10 h. The apparent volume of distribution (Vd/F) and apparent oral clearance (CL/F) are related to body size, the best predictor being body surface area. Rufinamide is not a substrate of cytochrome P450 (CYP450) enzymes and is extensively metabolized via hydrolysis by carboxylesterases to a pharmacologically inactive carboxylic acid derivative, which is excreted in the urine. Rufinamide pharmacokinetics are not affected by impaired renal function. Potential differences in rufinamide pharmacokinetics between children and adults have not been investigated systematically in formal studies. Although population pharmacokinetic modeling suggests that in the absence of interacting comedication rufinamide CL/F may be higher in children than in adults, a meaningful comparison of data across age groups is complicated by age-related differences in doses and in proportion of patients receiving drugs known to increase or to decrease rufinamide CL/F. A study investigating the effect of rufinamide on the pharmacokinetics of the CYP3A4 substrate triazolam and an oral contraceptive interaction study showed that rufinamide has some enzyme-inducing potential in man. Findings from population pharmacokinetic modeling indicate that rufinamide does not modify the CL/F of topiramate or valproic acid, but may slightly increase the CL/F of carbamazepine and lamotrigine and slightly decrease the CL/F of phenobarbital and phenytoin (all predicted changes were <20%). These changes in the pharmacokinetics of associated AEDs are unlikely to make it necessary to change the dosages of these AEDs given concomitantly with rufinamide, with the exception that consideration should be given to reducing the dose of phenytoin. Based on population pharmacokinetic modeling, lamotrigine, topiramate, or benzodiazepines do not affect the pharmacokinetics of rufinamide, but valproic acid may increase plasma rufinamide concentrations, especially in children in whom plasma rufinamide concentrations could be increased substantially. Conversely, comedication with carbamazepine, vigabatrin, phenytoin, phenobarbital, and primidone was associated with a slight-to-moderate decrease in plasma rufinamide concentrations, ranging from a minimum of ,13.7% in female children comedicated with vigabatrin to a maximum of ,46.3% in female adults comedicated with phenytoin, phenobarbital, or primidone. In population modeling using data from placebo-controlled trials, a positive correlation has been identified between reduction in seizure frequency and steady-state plasma rufinamide concentrations. The probability of adverse effects also appears to be concentration-related. [source] PRECLINICAL STUDY: Disposition of ,9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoproteinADDICTION BIOLOGY, Issue 3-4 2008Laurence Bonhomme-Faivre ABSTRACT P-glycoprotein (P-gp) plays a major role in drug efflux. All the transported substrates are more or less hydrophobic and amphiphatic in nature. Being lipophilic, ,9 tetrahydrocannabinol (THC), the main cannabis component, could be a potential P-gp substrate. The aim of this project was to determine the contribution of the mdr1a gene product to THC disposition. Therefore, oral THC and digoxin (substrate test for P-gp) pharmacokinetics have been investigated in the intestinal epithelium and in the brain capillary endothelium of CF1 mdr1a (,/,) mice (mice naturally deficient in P-gp). These pharmacokinetics were compared to THC and digoxin oral pharmacokinetics in wild type mice mdr1a (+/+) (not P-gp deficient). The application of Bailer's method showed that THC total exposure measured by the area under the plasma concentration time curve was 2.17-fold higher in CF1 mice naturally deficient in P-gp than in wild type mice after oral administration of 25 mg/kg of THC, and 2.4-fold higher after oral administration of 33 µg/kg of digoxin. As a consequence, the oral bioavailability of THC and digoxin was higher in naturally P-gp-deficient mice. We concluded that P-gp limits THC oral uptake and mediates direct drug excretion from the systemic circulation into the intestinal lumen. [source] Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphateINTERNATIONAL JOURNAL OF CANCER, Issue 9 2008Yoshinori Okamoto Abstract Raloxifene (RAL) significantly reduced the incidence of breast cancer in women at high risk of developing the disease. Unlike tamoxifen (TAM), an increased incidence of endometrial cancer was not observed in women treated with RAL. However, RAL, having two hydroxyl moieties, can be conjugated rapidly through phase II metabolism and excreted, making it difficult to achieve adequate bioavailability by oral administration in humans. As a result, higher doses must be administered to obtain an efficacy equivalent to that achieved with TAM. To improve oral bioavailability and antitumor potential, RAL diphosphate was prepared as a prodrug. RAL diphosphate showed several orders of magnitude lower binding potential to both ER, and ER, and weak antiproliferative potency on cultured human MCF-7 and ZR-75-1 breast cancer cells, as compared to RAL. However, RAL diphosphate has a much higher bioavailability than RAL, endowing it with higher antitumor potential than RAL against both 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats and human MCF-7 breast cancer implanted in athymic nude mice. The RAL prodrug may provide greater clinical benefit for breast cancer therapy and prevention. © 2008 Wiley-Liss, Inc. [source] ORIGINAL ARTICLE: Solubilization of vorinostat by cyclodextrinsJOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Issue 5 2010Y. Y. Cai BSc Summary Background:, Vorinostat (suberoylanilide hydroxamic acid) is the first histone deacetylase inhibitor approved by US FDA for use in oncology. However, as a hydrophobic acid, its limited aqueous solubility poses a problem for parenteral delivery. Such limited solubility may also affect its oral bioavailability. Objective:, The aim of this study was to evaluate whether cyclodextrins (CDs), common excipients used in pharmaceutical industry, could increase the aqueous solubility of vorinostat. Methods:, The actual aqueous solubility of vorinostat was investigated by phase-solubility method. Molecular simulation was employed to predict the interaction energy and preferred orientation of vorinostat in CD cavities. Results:, Phase-solubility studies indicated that the solubility of vorinostat (7·24 × 10,1 mm) was substantially increased when complexed with various CDs, in the following order: randomly methylated-,-cyclodextrin (RM-,-CD) > hydroxypropyl-,-cyclodextrin (HP-,-CD) > ,-cyclodextrin > hydroxypropyl-,-cyclodextrin > Hydroxypropyl-,-cyclodextrin > ,-cyclodextrin. RM-,-CD 300 mm increased vorinostat solubility to 70·8 mm, almost two orders of magnitude higher than the baseline solubility. Such findings were in good agreement with the results obtained from molecular simulation. Conclusion:, CDs, particularly RM-,-CD and HP-,-CD, increased vorinostat's solubility. Future studies could be focused on the application of HP-,-CD in parenteral delivery of vorinostat or using RM-,-CD as an oral absorption enhancer. Molecular simulation appeared to be a useful tool for the selection of appropriate CD as excipient for drug delivery. [source] Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention,JOURNAL OF INTERNAL MEDICINE, Issue 4 2004T. Hulgan Abstract. Objective., To determine whether a computerized decision support system could increase the proportion of oral quinolone antibiotic orders placed for hospitalized patients. Design., Prospective, interrupted time-series analysis. Setting., University hospital in the south-eastern United States. Subjects., Inpatient quinolone orders placed from 1 February 2001 to 31 January 2003. Intervention., A web-based intervention was deployed as part of an existing order entry system at a university hospital on 5 February 2002. Based on an automated query of active medication and diet orders, some users ordering intravenous quinolones were presented with a suggestion to consider choosing an oral formulation. Main outcome measure., The proportion of inpatient quinolone orders placed for oral formulations before and after deployment of the intervention. Results., There were a total of 15 194 quinolone orders during the study period, of which 8962 (59%) were for oral forms. Orders for oral quinolones increased from 4202 (56%) before the intervention to 4760 (62%) after, without a change in total orders. In the time-series analysis, there was an overall 5.6% increase (95% CI 2.8,8.4%; P < 0.001) in weekly oral quinolone orders due to the intervention, with the greatest effect on nonintensive care medical units. Conclusions., A web-based intervention was able to increase oral quinolone orders in hospitalized patients. This is one of the first studies to demonstrate a significant effect of a computerized intervention on dosing route within an antibiotic class. This model could be applied to other antibiotics or other drug classes with good oral bioavailability. [source] Radiosynthesis of [11C]ximelagatran via palladium catalyzed [11C]cyanationJOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, Issue 1 2008Anu J. Airaksinen Abstract N -hydroxyamidines (amidoximes) may be used in prodrug technology in improving oral bioavailability of drugs containing amidino functional groups. In the body, amidoximes are reduced quickly to amidines by enzymes that are present in several organs. Ximelagatran is a benzamidoxime and ethyl ester prodrug of melagatran, which is a thrombin inhibitor. Our aim was to develop a fast and efficient labeling route for the synthesis of [11C]ximelagatran ([11C]3) with a label in a metabolically stable position. [11C]3 was synthesized via a two-step synthesis sequence, starting from palladium catalyzed [11C]cyanation of its corresponding bromide precursor (2-[2-(4-bromo-benzylcarbamoyl)-azetidin-1-yl]-1-cyclohexyl-2-oxo-ethyl amino-acetic acid ethyl ester) (1), followed by a reaction with hydroxylamine. [11C]3 was synthesized with 27±17% total overall decay corrected yield (specific radioactivity of 2360±165,Ci/mmol at EOS), with a total synthesis time of 45,min. A fast and efficient labeling route for the synthesis of [11C]3 was developed. Copyright © 2008 John Wiley & Sons, Ltd. [source] The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humansJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 11 2009Masayuki Takahashi Abstract In order to elucidate the causes of the species differences in the oral bioavailability (BA) between cynomolgus monkeys and humans, the contributions of first-pass metabolism and intestinal absorption were investigated. Typical substrates of cytochrome P450 enzymes, UDP-glucuronosyltransferase enzymes and efflux transporters were selected, and the BA, the hepatic availability (Fh) and the fraction dose absorbed from gastro-intestinal tract (Fa*Fg) were calculated from pharmacokinetic analysis after oral and intravenous administration in cynomolgus monkeys. In addition, in vitro metabolism was investigated using liver and intestinal microsomes to evaluate the relationship between in vivo and in vitro results. The BA of cynomolgus monkeys was low compared with that in humans with most of the drugs tested, and not only Fh but also Fa*Fg contributed significantly to the low BA in cynomolgus monkeys. When Fh was evaluated in in vitro experiments, it correlated well with the in vivo Fh. However, although the metabolic activities of CYP3A4 substrates were high in cynomolgus monkey intestinal microsomes, those of the other substrates were low or not detected. These findings suggested that the species differences and low BA in cynomolgus monkeys could be mostly attributed not only to hepatic first-pass metabolism but also to the intestinal absorption process. © 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:4343,4353, 2009 [source] Genetically engineered normal flora for oral polypeptide delivery: Dose,absorption responseJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 8 2009Gagan Kaushal Abstract Genetically modified Lactococcus lactis (L. lactis), a probiotic bacterium, able to secrete ,-lactamase (29 kDa), was used as a vector for the oral delivery of ,-lactamase to the rats. Three different doses of L. lactis were administered to the rats, and the resulted ,-lactamase oral bioavailability was studied, and compared to the solution form. The oral administration of 1.2,×,107, 3,×,107, and 8,×,107 colony-forming units of L. lactis led to 145, 209, and 364 mU of ,-lactamase absorbed, and the corresponding bioavailability was 8.7%, 15.5%, and 20.8% based on the in vitro production of ,-lactamase by L. lactis. The oral administration of 504 mU and 1008 mU ,-lactamase free solution resulted in 30 and 47 mU absorbed, a bioavailability of 5.9% and 4.7%, respectively. L. lactis significantly (p,<,0.01) increased the oral bioavailability compared to the free solution form. A significant (p,<,0.01) increase in the MAT value as compared to the solution, demonstrated that L. lactis can be used as a sustained delivery system. In conclusion, there is a linear relationship between L. lactis dose and these absorption PK parameters within L. lactis dose range of the current study. © 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2573,2580, 2009 [source] Aqueous versus non-aqueous salt delivery strategies to enhance oral bioavailability of a mitogen-activated protein kinase-activated protein kinase (MK-2) inhibitor in ratsJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 1 2009Po-Chang Chiang Abstract A potent pyridine-containing MK2 inhibitor has recently been internally discovered. In pre-clinical dosing, the low solubility of the neutral form limited oral bioavailability and dose escalation in toxicity studies. A mesylate salt was developed as part of a formulation strategy to enhance both oral bioavailability and dose escalation orally in pre-clinical rat studies. Several non-aqueous systems were used to deliver the mesylate salt, which resulted in varied oral bioavailability. It was found that administration of an aqueous chaser immediately after dosing drastically increased the oral bioavailability of the salt. This finding implies that the quantity of water present in vivo is an important consideration when evaluating salts of free bases with low aqueous solubility in pre-clinical in vivo rat models where limited aqueous vehicle may be presented. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:248,256, 2009 [source] N-in-1 dosing pharmacokinetics in drug discovery: Experience, theoretical and practical considerationsJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 7 2008Kan He Abstract N-in-1 (or cassette) dosing pharmacokinetics (PK) has been used in drug discovery for rapid assessment of PK properties of new chemical entities. However, because of potential for drug,drug interactions this procedure is still controversial. This study was to retrospectively evaluate the N-in-1 dosing approach in drug discovery with an emphasis on the potential for drug,drug interactions. The systemic clearance, volume of distribution, oral bioavailability, and renal excretion of the 31 lead compounds in rats, dogs or chimpanzees were significantly correlated between the N-in-1 dosing and discrete studies with r values of 0.69, 0.91, 0.53, and 0.83 (p,<,0.005 for all), respectively. PK parameters for 11 quality control compounds which were involved in 194 N-in-1 studies for screening approximately 1000 compounds had coefficient of variations of less than 70%. The intrinsic microsomal clearances generated from the N-in-1 and discrete incubations were nearly identical (r,=,0.97, p,<,0.0001). The intrinsic clearances of quality control compound from the N-in-1 incubations were consistent with its discrete CLint estimate (cv: 5.4%). Therefore, N-in-1 dosing is a useful approach in drug discovery to quickly obtain initial PK estimates. Potential drug,drug interactions that result in confounding PK estimates do not occur as frequently as expected. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:2568,2580, 2008 [source] Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentinJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 6 2008Weiling He Abstract Thymopentin (Tp5) was loaded in poly-butylcyanoacrylate (PBCA) nanoparticles (NP) in order to enhance the oral bioavailability of Tp5. PBCA-Tp5-NP was prepared by nanoprecipitation methods. Dialyzing membrane method was employed to examine the in vitro release of PBCA-Tp5-NP in PBS, and Tp5 samples in the release medium were detected by HPLC. The cell proliferation test (3H-thymidine) was conducted to verify the PBCA-Tp5-NP bioactivity in vitro. The pharmacodynamical studies were performed on preimmunoinhibited rats and in flow cytometer. The size and the entrapment efficiency of PBCA-Tp5-NP were 178,±,39 nm and 92.21,±,1.08%, respectively. In vitro release data show that less than 60% Tp5 was released from lyophilized PBCA-Tp5-NP while 80% Tp5 was released from the colloidal PBCA-Tp5-NPs in 48 h. The proliferation test showed that PBCA-Tp5-NP had the similar effect as Tp5. The in vivo data showed that oral PBCA-Tp5-NPs had similar function as what intravenous Tp5 did. The oral bioavailability of Tp5 could be enhanced by PBCA nanoparticles. PBCA-Tp5-NP had the property of sustained-release and the efficacy of Tp5 was not changed after formulation. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:2249,2258, 2008 [source] Bioavailability and pharmacokinetic model for ritonavir in the ratJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 3 2007R. Lledó-García Abstract The aim of this study is to investigate in vivo the oral bioavailability of ritonavir and to evaluate the pharmacokinetic model that best describes the plasma concentration behavior after oral and intravenous administration. Male Wistar rats were intravenously administered at 3 mg dose of pure ritonavir and oral administered at 4.6,±,2.5 mg of diluted Norvir®. Blood samples were taken by means of the jugular vein for a 24 h period of time. An analytical high-performance liquid chromatography (HPLC) technique was developed in order to quantify ritonavir plasma concentrations. A nonlinear modeling approach was used to estimate the pharmacokinetic parameters of interest. Results showed that a two-compartmental model with zero-order kinetic in the incorporation process of ritonavir into the body better fitted intravenous and oral data. The estimated oral bioavailability by means of noncompartmental and compartmental approaches resulted in 74% and 76.4%, respectively. These values confirm the ones obtained by other authors in the rat. In conclusion, a zero-order kinetic in the incorporation process at the administered doses suggests the saturation of the possible specialized transport mechanisms involved in the incorporation of ritonavir into the body. These results could justify the use of low doses of ritonavir when improving the bioavailability of other protease inhibitors (PIs) is required. © 2006 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci [source] | |||||||||||||||||||||||||||||||